Bio-Techne (TECH)

• Market cap: $10.3B
• 1 day: -0.87%
• 5 days: -3.98%
• 1 month: -17.56%
• 3 months: -8.63%
• 6 months: -10.64%
• Year to date: -9.18%
• 1 year: -9.48%
• 5 years: 26.03%
• 10 years: 165.85%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Employees: 3,100

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

921% more call options, than puts

Call options by funds: $12.9M | Put options by funds: $1.27M

36% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 50

12% more repeat investments, than reductions

Existing positions increased: 212 | Existing positions reduced: 189

1.6% more ownership

Funds ownership: 96.83% [Q3] → 98.43% (+1.6%) [Q4]

0% less funds holding

Funds holding: 552 [Q3] → 551 (-1) [Q4]

8% less capital invested

Capital invested by funds: $12.3B [Q3] → $11.2B (-$1.04B) [Q4]

40% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 6 (-4) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $68 5% upside
• Avg. target: $82 26% upside
• High target: $90 39% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Baird Catherine Schulte 10% 1-year accuracy 2 / 20 met price target	5% upside $68	Neutral Downgraded	19 Feb 2025
RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target	23% upside $80	Sector Perform Maintained	6 Feb 2025
Scotiabank Sung Ji Nam 39% 1-year accuracy 9 / 23 met price target	39% upside $90	Sector Outperform Maintained	6 Feb 2025
Keybanc John Vinh 45% 1-year accuracy 23 / 51 met price target	39% upside $90	Overweight Maintained	6 Feb 2025